The Potential Role of CAR T Therapy in AL Amyloidosis

EP: 1.Exploring the Landscape Surrounding Light Chain Amyloidosis

EP: 2.Expert Perspectives on Differentiating Signs and Symptoms in AL Amyloidosis Diagnosis

EP: 3.Exploring Diagnostic Approaches for Patients with Light Chain Amyloidosis

EP: 4.Current Treatment Landscape for AL Amyloidosis

EP: 5.Unmet Needs and Treatment Considerations in Managing AL Amyloidosis

EP: 6.Treatment Strategies Using Monoclonal Antibodies in AL Amyloidosis

EP: 7.Optimizing Treatment Management Strategies in AL Amyloidosis with CD38-Directed mAbs

EP: 8.Addressing Challenges in Managing AL Amyloidosis with Cardiac Involvement

EP: 9.The Role of Cardiac Staging in Patients with AL Amyloidosis

EP: 10.Novel Treatment Approaches with mAbs Targeting Amyloid Deposits: Insights from VITAL

EP: 11.AFFIRM-AL: Birtamimab in Patients with Mayo Stage IV AL Amyloidosis

EP: 12.Expert Insights on Pooled Safety Data from the PRONTO and VITAL trials

Now Viewing

EP: 13.The Potential Role of CAR T Therapy in AL Amyloidosis

EP: 14.NEXICART-1: Safety and Efficacy of NXC-201 in AL Amyloidosis

EP: 15.Looking Ahead: Future Perspectives on AL Amyloidosis

This is a video synopsis/summary of a Peer Exchange involving Heather Landau, MD; Vaishali Sanchorawala, MD; and Jeffrey Zonder, MD.

For previously treated patients with relapse/refractory light chain (AL) amyloidosis, an unmet medical need persists as there are currently no approved drugs in this space. Despite the success of the ANDROMEDA trial, where 60% of patients achieved a complete hematologic response, 40% did not meet this bar, highlighting the need for effective second-line therapies. The challenge intensifies when patients experience progression during daratumumab maintenance. The role of chimeric antigen receptor (CAR) T cells in this patient population is being explored, considering their revolutionary impact on hematologic malignancies, particularly in multiple myeloma.

Two B-cell maturation antigen (BCMA)-directed CAR T-cell agents, cilta-cel and ide-cel, have shown exceptional activity in various lines of therapy for multiple myeloma. In AL amyloidosis, BCMA is expressed on amyloidogenic plasma cells, providing a rationale for CAR T-cell studies. However, challenges arise due to organ dysfunction associated with amyloidosis, raising concerns about the capacity of affected organs to withstand potential adverse effects like cytokine release syndrome and neurotoxicity associated with CAR T-cell therapy. Research aims to decipher the mechanism of action and assess the suitability of CAR T cells for patients with AL amyloidosis.

Video synopsis is AI-generated and reviewed by OncLive^® editorial staff.